Literature DB >> 8854083

Antigen-processing polymorphisms in chronic hepatitis C infection.

T Höhler1, G Gerken, P M Schneider, K H Meyer zum Büschenfelde, C Rittner.   

Abstract

BACKGROUND: Cytotoxic T cell (CTL) responses may influence the course of a hepatitis C infection. CTL recognize viral peptides on HLA class I molecules. Antigenic peptides for class I presentation are generated by proteasomes and transported into the endoplasmic reticulum by the TAP proteins. It is unknown whether polymorphisms of the antigen-processing genes might influence the development of chronic hepatitis C.
METHODS: 75 patients with chronic hepatitis C and 99 unrelated controls were typed for TAP and LMP2 polymorphisms. Typing was done by allele-specific PCR techniques and PCR with subsequent single-stranded confirmation polymorphism (SSCP) analysis.
RESULTS: Apart from minor increases of the TAP2*0101 allele and LMP2 heterozygotes in the chronic hepatitis group there were no statistically significant differences between the two groups.
CONCLUSIONS: These findings suggest, that disease association for chronic hepatitis C does not extend beyond the HLA-DQ locus. Although TAP and LMP play an important role in the processing of viral antigens, their limited polymorphisms do not show any association with the development of chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8854083

Source DB:  PubMed          Journal:  Exp Clin Immunogenet        ISSN: 0254-9670


  2 in total

1.  Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease.

Authors:  H L Tillmann; D F Chen; C Trautwein; V Kliem; A Grundey; A Berning-Haag; K Böker; S Kubicka; L Pastucha; W Stangel; M P Manns
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Significance of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in susceptibility to dengue viral infection.

Authors:  R Soundravally; S L Hoti
Journal:  J Clin Immunol       Date:  2008-05       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.